. Author manuscript; available in PMC: 2019 Jul 24.

Published in final edited form as: J Am Acad Dermatol. 2018 Jan 10;78(3):560–578. doi: 10.1016/j.jaad.2017.10.007

Table XV.

Level of evidence and strength of recommendations for the follow-up of cSCC and reducing risk for future tumors

Recommendation	Strength of recommendation	Level of evidence	References
Annual follow-up skin cancer screening	A	I	^{112–115,131,132}
Skin self-examination and sun protection after cSCC	A	III	Expert opinion
Against the use of topical and oral retinoids^*
• Tretinoin	A	I, II	^119,120,133
• Acitretin	B	I	¹²¹
• Isotretinoin	A	I	^125,134
• Oral retinol	A	I	^125,135
Use of acetretin for SOTR patients	B	I	¹²³
Against chemoprevention using
• Celecoxib	B	I	^127,136
• DFMO	A	I	^137,138
• Oral nicotinamide	B	I	¹²⁶
Against dietary supplementation with
• Selenium	A	I	^128,129
• β-Carotene	A	I	¹³⁰

cSCC, Cutaneous squamous cell carcinoma; DFMO, α-difluoromethylornithine; SOTR, solid organ transplant recipient.

Non-SOTRs.